Cytochrome-P450-2C9 (CYP2C9) metabolizes wide range of drugs and highly express in human liver. Various mutations of CYP2C9 (R144C, I359L etc.), associated with drugresponse, are highly diverse. We aimed to investigate the genetic diversity of CYP2C9 in Indian-subcontinent, using 1278 subjects from 36 populations. High frequency of CYP2C9*3 
Introduction
Heterogeneous drug response is the major hurdle in the successful treatment of diseases and depends on the genetic variations of drug metabolizing enzyme genes. Cytochrome P450 (CYP) family is an important enzyme of ADME (related to absorption, distribution, metabolism and excretion of drug) genes, of which CYP2C9 is the major constituent of CYP2C subfamily in human liver. It metabolizes wide range of drugs including anticoagulant (warfarin), non-steroidal anti-inflammatory (celecoxib, diclofenac), anti-diabetic (netaglinide, tolbutamide), anti-hypertensive (irbesartan, losartan) and anti-epileptic (phenytoin) 1 . Several variations in CYP2C9 have been reported which affects metabolism of the drug. Most notable variations are CYP2C9*2 (R144C) and CYP2C9*3 (I359L) which decreases 12% and 5% enzyme activity, respectively 2 . Interestingly, these variations are highly heterogeneous among world population; (1) 8-19% and 3.3-16.3% in Caucasian; (2) 0-0.1% and 1.1-3.6% in Asian; (3) 2.9% and 2.0% in African-American; and (4) 0-4.3% and 0-2.3% in Black/African, respectively 3 . Moreover, other rare and functionally relevant variations were also reported in various populations, which includes; (1) CYP2C9*6, 0.6% frequency in African-Americans 4 ; (2) CYP2C9*4, 0.5% in African-Americans and 6% in allele 9 , however, Anil et al (2014) did not observe any homozygous CYP2C9*3/*3 genotype.
Many studies have shown that the variations in CYP2C9 are associated with therapeutic heterogeneity in Indian populations. CYP2C9*2 and *3 has been reported with less hydroxylation (or metabolism) of phenytoin in vivo in South-Indian populations 10 , comparative to wild type CYP2C9*1. Ramasamy et al. (2007) reported phenytoin toxicity in a patient with normal dose of 300mg/day, who had CYP2C9*3/*3 genotype 11 . The same symptoms were reported by Thakkar, A. N. et al. (2010) in South-Indian populations 12 . Many studies have also demonstrated that the Indian populations need high dose of warfarin and phenytoin compared to Caucasians 12 . Both of these drugs are metabolized by CYP2C9. Some of the drugs, metabolized by CYP2C9 have narrow therapeutic index e.g. warfarin, phenytoin and tolbutamide. This is the reason that small change in the activity of CYP2C9 may cause major changes in individual's response.
Considering the high genetic diversity in Indian sub-continent, we explore functionally relevant variations in CYP2C9, in the present study. The outcome can be utilized to understand heterogeneous therapeutic response and in development of personalized therapy in Indian sub-continent.
Material and methods

Details of samples
In total, 1278 samples were selected for the study. To find the distribution of CYP2C9 allele/genotype frequency within Indian subcontinent, 36 populations of different linguistic groups and geographical locations were selected (Table S1 ) 9, 13 ; and further compared with populations of 1000 genome project. Present work has been approved by the Institutional Table S2 . Polymerase chain reaction (PCR) was performed in 10.0 µl solution, which contains 5.0 µl of 2x EmeraldAmp GT PCR master mix, 10-20 ng of genomic DNA and 0.1 pmole (final concentration) of each primer. Thermal cycling conditions used are as follows: initial denaturation step of 5 min at 94ºc, followed by 35 cycles of denaturation step of 30 sec at 94ºc, annealing step of 30 sec at their respective melting temperature, extension step of 2 min at 72ºc, followed by single step of final extension of 7 min at 72ºc. PCR products were cleaned with Exo-SAP-IT (USB, Affymetrix, USA) with recommended protocol of the manufacturer. Cleaned PCR product (1.0 µl) has been subjected to sequencing PCR using BigDye terminator (v3.1) cycle sequencing kit (Applied Biosystem, USA) and analyzed using ABI 3730xl DNA sequencer. AutoAssembler (v1.0) was used for assembling and manual editing of sequence data.
Distal effect of L362V on kinetics of CYP2C9: molecular dynamics simulation
Preparation of 3D (3 dimensional) structure
We performed the molecular dynamics simulation with Gromacs (version 5.0.2) 14 . Starting structure of CYP2C9 was obtained from PDB (code: 1OG5). We removed warfarin drug from 1OG5 with Chimera (version 1.11) 15 and utilized in the further structure modifications. In total, 7 amino acids (K206E, I215V, C216Y, S220P, P221A, I223L and I224L) were substituted in wild type CYP2C9, to enhance the crystallization 16 . Hence, we modified back 1OG5 to wild type sequence with FoldX (version 2.6) and further utilized to generate mutant proteins. We generated 3D structure of L362V, with FoldX.
Docking of warfarin drug
Since, warfarin was located farther from heme center and in catalytically non-reactive stage;
we performed docking with AutoDock Vina (version 1.1.2) to obtain putative functional confirmation of drug in the active site of CYP2C9 17 . Autodock tools were used for generating partial charges of warfarin and CYP2C9 using Gasteiger method 18 . Confirmation of warfarin, having lowest binding energy, was selected in further analysis.
Simulation
To perform molecular dynamics simulation, Gromacs (version 5.0.2) was used 14 . We assigned the partial charges of warfarin and oxyferryl state of heme group, as described by For all ligand bound models (wild-type/mutant), initially we placed the molecule in 1nm cubic box and then solvated it with TIP3P water molecules; and neutralize the system with sodium (NA) molecules. Energy minimization of the system was performed in 10,000 steps with steepest descent minimization algorithm. The potential energy of system has been demonstrated in Figure S1 . Further, we equilibrated the system at ~310K (normal human body temperature) and at pressure ~1 bar in 20 and 100 pico seconds (ps) respectively in 2 different steps ( Figure S2 ). After this, system was simulated for 15 nano seconds (ns), in 4
replicates. To calculate the rolling mean in 100 ps, we utilized the zoo package of R 22 .
Results and discussions
Diversity of CYP2C9*3 in Indian populations
The AC (rs1057910/ CYP2C9*3) is a non-synonymous mutation, which replace Isoleucine with Leucine (ATT>CTT; Ile359Leu; low enzyme activity Indian sub-continent, high local heterogeneity was observed and any correlation with geographical location does not exist ( Figure 1A and Table 1 ). It is evident in isofrequency map that Indian populations have high frequency of CYP2C9*3, comparative to other world populations ( Figure 1A) . We observed, decreasing gradient of "C" allele frequency from Indian subcontinent to Europeans ( Figure 1A) . 
Novel non-synonymous variant L362V
We observed a non-synonymous mutation L362V in Indian population at higher frequency.
Since, this mutation was observed in higher frequency and present only in Indian populations;
we further explored it in 1000 genome project samples. We found that this variant and FeO in simulation of mutant, comparative to wild-type CYP2C9 (Figure 4, 6 and S4) .
The simulations predict the less kinetic activity of the mutant (L362V) CYP2C9, comparative to wild-type.
Other rare variants
Besides these, a few rare variants have also been observed in this study. The nonsynonymous C>T mutation (rs28371685), which replace arginine with tryptophan (R335W) and determine CYP2C9*11 haplogroup was found only in 3 individuals (0.2347%, 1 each in Chenchu, Telagas of Andhra Pradesh and Mudliar of Tamil Nadu). Besides this, 2 novel nonsynonymous mutations F482L and T283S were found in 2 individual (0.0782%), each in Mizo (Mizoram) and Warli (Maharashtra), respectively.
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